期刊文献+

石杉碱甲保护人脑微血管内皮细胞损伤的体外实验研究 被引量:1

Protect Effects of Huperzine A on Methylglyoxal Induced Injury in the Cultured Human Brain Microvascular Endothelial Cell in Vitro Experimental Study
原文传递
导出
摘要 目的体外实验研究石杉碱甲对人脑微血管内皮细胞(human brain microvascular endothelial cells,HBMEC)损伤的保护作用和机制。方法在培养的HBMEC上,利用丙酮醛诱导细胞损伤,通过MTT检测细胞活力,LDH、SOD活性试剂盒及caspase-3活性试剂盒检测细胞损伤情况,观察石杉碱甲的作用和机制。结果石杉碱甲呈浓度依赖地保护MGO诱导的细胞损伤,在10-5mol·L-1时呈最大保护作用。丙酮醛能诱导HBMEC的SOD活性下降,而石杉碱甲(10-6,10-5mol·L-1)能逆转这种作用。进一步研究发现石杉碱甲能抑制丙酮醛诱导的caspase-3活性上升。结论石杉碱甲对丙酮醛诱导的HBMEC的损伤具有保护作用,这可能与其抗自由基和抗凋亡作用有关。 OBJECTIVE To evaluate the effects ofhuperzine A on the methylglyoxal(MGO) induced injury in the culturedhuman brain microvascular endothelial cell(HBMEC).METHODS HBMEC cell line was chosen to induce MGO injury.Cell vitality was measured by using MTT,LDH release,SOD activity were tested by kits.Cell apoptosis was measured by caspase 3 activity.RESULTS Huperzine A dose-dependently protected MGO induced HBMEC injury.At 10-5mol·L-1 ofhuperzine A manifested the maximum effects.MGO increased SOD activity,which were reversed by pretreatment of venlafaxine(10-6 and 10-5mol·L-1).Furthermore,huperzine A(10-6 and 10-5mol·L-1) also decreased MGO induced caspase 3 activity increasing.CONCLUSION Huperzine A protected MGO induced injury in the cultured HBMEC,which may be involved its anti-oxidation and anti-apoptosis activity.
出处 《中国现代应用药学》 CAS CSCD 2015年第3期277-281,共5页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省自然科学基金(Y2100294) 浙江省卫生厅项目(2011KYA073 2014KYA100) 浙江省中医药项目(2014ZA067)
关键词 石杉碱甲 脑微血管内皮细胞 丙酮醛 凋亡 huperzine A human brain microvascular endothelial cell methylglyoxal apoptosis
  • 相关文献

参考文献3

二级参考文献255

  • 1陈超刚,苏宜香,严励,黄德芳,黎锋,程桦.低血糖生成指数膳食对糖尿病患者代谢和营养摄入状况的影响[J].中国糖尿病杂志,2007,15(8):495-497. 被引量:25
  • 2Rose G. Detection of high coronary risk. Postffad Med J, 1976, 52: 452-455.
  • 3Wilson PW, D'Agostino RB, Levy D, a al. Prediction of coronary heart disease using risk factor categories. Circulation, 1998, 97: 1837-1847.
  • 4Gnmdy SM, Balady GJ, Criqui MH, et al; Atrmican Heart Associa- tion. Primary prevention of coromry heart disease: guidance from Framingham a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation, 1998, 97: 1876-1887.
  • 5Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360: 7-22.
  • 6National Cholesterol Education Progam (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002, 106: 3143 -3421.
  • 7Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation, 2002, 106: 388-391.
  • 8Mosca L, Benjamin El, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation, 2011, 123: 1243-1262.
  • 9Sacco RL, Kargran DE, Gu Q, et al. Race-ethnicity and determinants of intmcranial atherosclerotic cerebral infarction: the Northern Manhattan Stroke Study. Stroke, 1995, 26: 14-20.
  • 10D'Agostino RB St, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation, 2008, 117: 743-753.

共引文献24

同被引文献15

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部